⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PALI News
Palisade Bio, Inc. Common Stock
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
globenewswire.com
PALI
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
globenewswire.com
PALI
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
globenewswire.com
PALI
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
globenewswire.com
PALI
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
globenewswire.com
PALI
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
globenewswire.com
PALI
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
PALI
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
globenewswire.com
PALI
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
globenewswire.com
PALI
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
globenewswire.com
PALI